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Today urinary excretion of estrogen äs an
indicator of possible pregnancies at risk is an
accepted parameter. For a long time excretion
of estrogen was considered äs a so-called feto-
placental indicator; since both fetus and pla-
centa participate in estriol synthesis. However,
recent findings indicate [7, 22, 23] that the fetus
is, to some extent, independent of the pla-
centa äs far äs the synthesis of estriol pre-
cursors is concerned. It has also been demon-
strated that the capacity of the placenta to form
aromatic compounds is not decreased but rather
elevated in severely impaired nutrition [21]. Heüce
decreased estrogen excretion is more probably
due to limited synthesis in the fetus than in the
placenta. The lack of placental sulfatase is an
exception that is hardly of quantitative im-
portance [6, 8]. Hence the rate of estrogen ex-
cretion may be considered a fetal rather than a
fetoplacental parameter.
Usually an impairment of the nutritive function
of the placenta that is chronic in nature is the
basis of the endocrinologically assayable danger
to the fetus. If urinary estrogen excretion is
decreased it must be assumed that the fetus has
already been damaged. Hence for perinatal
diagnostic purposes it is desirable to use a
purely placental indicator that might in-
dicate danger earlier than estrogen excretion
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and that permits us to distinguish between
fetal and placental malfunction. Three hor-
mone tests are usually applied: HPL (human
placental lactogen) in serum; pregnandiol in
urine äs an indicator of progesteron metabolism
and plasma progesteron.
HPL indicates the rate of proteinsynthesis in
the placenta and pregnandiol its steroid bio-
synthesis. The introduction of radioimmuno-
logical tests for HPL has feduced pregnandiol
determinations with their well known draw-
backs related to urinary analyses. Pregnandiol
determinations very often gave false normal
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results [11]. The value of HPL determinations
has invited contradictory opinions [3, 4, 12, 16,
18, 19, 20]. Our own data also indicate that HPL
in addition to estrogen determinations does
give Information on placental function but
that this represents no gain in time (unpublished
data). Time, however, is of utmost importance.
We have retained the use of urinary analysis.
Our results with pregnandiol using a previously
reported method [24] do not agree with those of
KELLER [11]. We asked whether estriol excretion
was really a fetal parameter. Hence both estrogen
and pregnandiol were determined in 24-houn
urine samples. A total of 2500 combined hormone
analyses were performed in 500 cases from which
the 222 reported pregnancies at risk were chosen.
l Material and Method
Estrogen and pregnandiol were determined äs
described previously [24, 25] using internal
Standards. The method is reliable. Normal va-
lues were obtained from a large number of
normal women between the 20th and 40th
weeks of pregnancy [24, 25]. 24-hour urines were
examined for creatinine (picric acid method,
TECHNICON autoanalyser) to test for correct
urine collections. Not only "normal" creatinine
excretion but also the constant rate of intraindi-
vidual excretion served äs criteria. Only 24-hour
urines were tested. Only the following pregnant
women were included:
1. At least 3 hormone tests1).
2. Last hormone analysis at the earliest one
week before the end of pregnancy.
3. Pregnancy at risk according to case history or
finding; with suspicion of chronic impairment
of the feto-placental unit.
4. No acute renal disease and no penicillin
treatment [26].
Hormone excretion was considered to be patho-
logical if
x) Only a few exceptions were made; e. g. in severe cases,
when pregnancy was terminatgd for clinical reasons and
the very low hormone values, or if suspicion of fetal death
was confirmed endocrinologically.
1. there was no normal rise in hormone excretion; but a
stagnant level, particularly for estrogen — for a period
of at least 4 weeks, even if this was within the normal
ränge
2. there was a fall in hormone excretion within a few days,
even within the normal ränge, to less than 50% of the
initial value,
3. there was a prolonged slow decline in hormone excre-
tion — even within the normal ränge
4. many of the values were within a doubtful pathological
ränge [8, 9] or below that ränge
5. particularly estrogen excretion showed „heterogeneous
oscillations", this being a pattern of exretion that occurs
frequently in less severe cases of intrauterine growth
retardation, that can only be identified at high frequen-
cies of analysis and that i s discussed below.
The requirement for "correct Information" was
met if
1. pathological hormone values were obtained in clinically
ascertained risk cases,
2. if an injured child was bor n after an uneventful preg-
nancy and if pathological hormone values led us to
except impairment,
3. the case history led us to expect a pregnancy at risk
with the present pregnancy being normal with a normal
child äs expected from normal hormone values,
4. a normal child was delivered to an EPH gestosis with
a possibly impaired placental function äs indicated by
pathological pregnandiol excretion, where normal estro-
gen values led us to expect a normal child,
5. a normal child at term was delivered t o a woman with
slight EPH gestosis with normal estrogen and pregnan-
diol values,
6. after the expected term" had been exceeded, a healthy
füll term baby, not postmature, was delivered äs was
expected from normal pregnandiol values indicating
normal placental function and from rising estrogen
values, indicating that term had not been exceeded,
7. a postmature baby was delivered after normal term had
been exceeded with pathological pregnandiol values in-
dicating decreasing placental function and with decrea-
sing estrogen values indicating postmaturity.
The following risks were included: EPH
gestosis (38.7%), suspicion of impairment of
nutritive placental function without EPH
gestosis (16.2%), imminent premature deli-
very (13.9%), postmaturity or uncertain term
(13.5%), suspicion of impairment of placental
function äs judged from the case history (9.9%),
hemorrhage (6.7%), diabetes (0.9%).
First all data were computed. The results of
hormone analyses without further differentiation
were expected to indicate whether risk to the
fetus had been assessed. Thereafter a detailed
etiological analysis was performed.
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Tab. I. Reliability of estrogen and pregnandiol urinary excretion if assessed individually or together




















































Tab. II. Separation of pregnancies into risk groups depending on the combined excretion of estrogen and pregnandiol.
Types of risk in the groups. Frequency of SGA infants in the groups.





P normal I 55
E normal
P pathol. II 52
E pathol.
P normal III 23
E pathol.







































































































A total of 2211 estrogen and pregnandiol de-
terminations were performed in 222 pregnancies;
an average of 9 daily urines being analysed per
patient. Reliability was separately determined for
each hormone and determined äs a diagnostic
unit. The risk is considered to be determined
when both hormones are assayed, if the ex-
cretion of either hormone is pathological; results
are shown in Tab. L
The lowest rate of false normal findings is
observed if both hormones are evaluated.
These are five cases with premature labor, of
whom three resulted in premature births and two
in the delivery of füll term babies after successful
tocölysis. The 6th case is genuinely postmature
with the delivery of an otherwise healthy child.
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In none of these cases with normal hormone
values was a small for date infant delivered.
2.2 Risk groups and types of risk
We shall deal with the four possible hormone
combinations separately. Risk groups will be
delineated at the same time. The four groups at
risk are devided according to the type of risk.
The largest number of SGA infants is found in
risk group IV (pathological excretion of both
hormones). Results are summarized in Tab. II.
2.2.1 Risk group I
As expected this includes mainly pregnancies
that were at greater risk because of case
history or postmaturity but resulted after
normal clinical courses in a healthy füll term
baby. The 15 cases of light, mostly mono-
symptomatic (slight hypertension) EPH.gestosis
belong here. As already mentioned the risks
"imminent premature delivery" and "post-
maturity" may belong to group I and cannot be
securely distinguished by combined hormone
determinations.
When deciding whether estrogen excretion is
rising (term has not yet occurred) or falling
(postmature) it must be remembered that daily
variations in estrogen excretion are about 20%
(see below). As expected there is no intrauterine
growth retardation in group I.
2.2.2 Risk group II
The hormonal picture is typical for EHP gestosis
and is most frequently found if examination is
begun early äs soon äs signs of hypertonia are
observed. In light or well treated cases there is
no change in the excretion of hormones up to
the end of gestätion. Predominantly a normal
child is delivered. Only 6 out of 66 maldeveloped
children showed the hormone picture of group II.
In three of these an EPH gestosis was also
present, in two bleeding occurred and in one
premature labour set in. Untreated EPH
gestosis terminates within weeks or months
mostly in group IV indicating fetal in Jury äs
judged from altered estrogen excretion. There
is a very small number of cases with premature
labor which corresponds with a small corre-
lation between imminent premature labor and
impairment of placental function. Intrauterine
growth retardation was found in 11.5%. This
frequency indicated that this type of risk is not
always discovered by estrogen determina-
tions alone.
2.2.3 Risk group III
Injury of the fetus without demonstrable endo-
crine impairment of placental function (patho-
logical placental parameter) should be the ex-
ception, rather than the rule. The small number
of cases thus agrees with our expectation. Yet
this hormone pattern, in comparison to that of
group II, indicates a greater degree of risk, äs
shown by the greater frequency of SGA infants
in group III. The hormone excretion in anence-
phaly is typical for group III (one case). Hence
pathological estrogen excretion with normal
excretion of pregnandiol should raise sus-
picion of this anomaly. The six pregnancies
with intrauterine SGA infants in group III
consisted of 2 EPH gestoses, three premature
labors and one functional disturbance of the
placenta without other Symptoms.
2.2.4 Risk group IV
As expected this contains the largest number of
cases, severe gestoses, most infants small for
date and the smallest number of false patho-
logical results (one case). The risk type "EPH
gestosis" and "suspected impairment of nutri-
tive placental function" form 67.3% of all cases
of this group. A total of 63 SGA infants was
born. The mothers of 51 of these had the hor-
mone excretion of risk group IV (frequency
55.4%). In 24 of these 51 mothers a usually
severe EPH gestosis was present; in 18 the case
history or the present state indicated impairment
of the nutritive function of the placenta; in the
remaining 9 premature labor or hemorrhage were
found. The relatively large percentage of SGA
infants whose mothers, except for a history of
placental insufficiency or low fundus, showed no
clinical signs of chronic placental impairment,
was surprising. A total of 19 SGA newborns
(one from group III), i. e. 30.1% of the total
number, was found. Such a high incidence of
SGA infants in clinically apparently normal
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pregnancies underlines the need for general
endocrine surveillance during gestation.
The above statistics confirm the expectation that
chronic placental insufficiency with or with-
out EPH gestosis is one of the main indica-
tions for endocrine diagnosis. Figs. l and 2
give examples.
Fig. l shows the typical estrogen and pregnandiol
excretion pattern in a 32-year-old woman (primi-
para) with suspected intrauterine growth re-
tardation without EPH gestosis. At first a normal
rise in estrogen excretion was observed. The
mean excretion of hormones of the control group
upper/lower limit of the normal ränge
suspected patbological zone = fetal/placental alarm-zone
phase of compensation




20 2 28 32 36 40
weeks of pregnancy
Fig. 1. Example o£ pregnancy of risk-group IV. 32 year
old primipara, no EPH-gestosis. Newborn: 2700 g/50 cm,
APGAR 10/10.
first pathological result would have raised no
suspicion if it had been obtained alone. The
pregnandiol excretion curve, however, indicated
right from the Start the presence o£ considerably
impaired placental function. The further course
shows alternating phases of placental compen-
sation (rising pregnandiol excretion) and de-
pression (falling excretion). Twice (31st/32nd
and 36th/37th week) the maximum of pregnandiol
excretion shows a clear compensation by the
fetus (a rise of the previously unältered estrogen
excretion). This can be interpreted to indicate a
reaction to the transient improvement of placental
function. The general endocrine finding clearly
indicates a growth retarded fetus, which, how-
ever, need not be severely damaged. A newborn
weighing 2700 g/50 cm with an ApGAR-score of
10/10 corresponds to that conclusion.
Fig. 2 shows two cases with severe gestosis. Both
curves are examples for successfully and early
treated cases. The two single values in the 33rd
week show the end of a risk pregnancy that was
not controlled and that was treated too late. The
fetus died in utero.
Casel
A 26-year-old secondipara, EPH gestosis in the 2nd half
of the Ist pregnancy (weight 107 kg), child 4200 g/55 cm.
This pregnancy: hypertension from 12th week, endocrine
control started from 20th week. Alternate continuous out-
patient and hospital treatment (Lasix®, Catapresan®,
Hygroton®). Weight gain from 90 to 109 kg before delivery
ending in uncomplicated birth of healthy mature girl.
3000 g/50 cm; APGAR 10/10. Strongly infarcted placenta.
The start of a critical change can be observed in the excre-
tion of both hormones.
This case is proof that good treatment of EPH
gestosis can prevent severe chronic distur-
bance in the feto-placental unit and hence the de-
livery of an SGA infant. The case also shows what
we consider to be "heterogeneous variations" in
hormone excretion. A quick glance at estrogen
excretion does not seem to indicate fetal risk.
Most values appear normal. However, it can be
seen that for both hormones periods of com-
pensation and depression traverse the whole
ränge of normal values and that they vary by
more than 50% within a few days. This does
not occur normally. Thus in one pregnant woman
in the 23/24th week the Standard deviation of
J. Perinat. Med. 3 (1975)




20 24 28 32 36 40
weeks of pregnancy
Fig. 2. Example of two pregnancies with severe EPH-
gestosis.
Gase l: Supervision since the twentieth week. Newborn:
3000 g/50 cm, APGAR 10/10.
Gase 2: Single determination during the 33rd week, no
supervision. Fetal death during the 33rd week.
estrogen excretion for 10 successive daily periods
was s = 3.5 mg/24 hrs with χ = 18.1 mg/24 hrs
and V = 19.1% and &,= 4,4 mg/24 hrs, χ = 18,9
mg/24 hrs, V = 23,2% for pregnandiol excre-
tion. The coefficient of Variation for creatinin
excretion was V = 5.3%. In another ten 24-hour
urine samples obtained in the 38/39th week in
another woman we found s = 8.4 and χ = 51.8
mg/24 hours and V = 16.2% for estrogen and
s = 5.2, χ = 58.6 mg/24 hrs and V == 8.8% for
pregnandiol. The coefficient of Variation for in-
traindividual creatinine excretion was 9.0%. These
values may be considered to be representative.
Variations that exceed these values, even though
they lie within the norm, must be viewed s
pathological. We suggest that this be called
"heterogeneous variations".
Case 2 also was a severe EPH gestosis with no
hormonal control or treatment. The dead infant
(1650 g, 44 cm) requires no comment.
2.3 Other problems
a) Critical limit of hormone excretion
Some workers [17] consider an endocrine para-
meter to be not only normal or pathological but
assign it a certain weight for estimating the risk,
by evaluating its transverse position according
to a point System, (e. g. estrogen excretion = low
normal = l point, in dubious pathological r nge
2 points etc.).
This leads to the following question: Is there a
critical lower limit for estrogen excretion below
which it is better to terminate pregnancy, i. e.
for which chances for survival are better outside
the uterus than within.
Our data cohtain 10 perinatal deaths, of which
one was an anencephalus. Another two can be
eliminated since they died before the 30th week
of gestation. Of the remaining 7, in four the
fetus died in utero, in 3 cases within 12 days after
birth. Hence there are very few cases. Fig. 3
shows the lowest estrogen value found in 8
pregnancies between the 30th and 40th week.
Evidently there is a crossing over of values, the
Line of Iowcst estrogen values of four cases with intrauterin
X X fetal death
Line of lowest estrogen values of three pregnancies; one child
X X survived, two children died poitnatally
Curve of estrogen of a pregnancy with newborn which diedχ ·~—.~—.— χ . »tpostnatally
20 24 28 32 36 40
weeks of pregnancy
Fig. 3. Critical limit of estrogen excretion.
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lowest value being for a surviving cbild (6 mg/
24hrs in the 34th weck). The dot dash line
shows estrogen excretion for a severe EPH
gestosis. The child died 3 days after delivery.
Hence, with great reservations it may be con-
cluded that:
1. There is no lower limit of estrogen excretion.
2. Estrogen values between 6 and 10 mg/24 hrs
are compatible with intrauterine life in the
last 6 weeks of gestation. Postnatal survival,
however, is rare.
3. If estrogen values fall, then at the latest for a
value of 10 mg/24 hrs pregnancy should be
terminated.
4. If estrogen values show a tendency to rise
from low initial values there is less risk of
intrauterine death. However, the postnatal
v ; risk remains.
5. Estrogen excretion of less than 6 mg/24 hrs
in the last 10 weeks of pregnancy is incom-
patible with intrauterine life (rare exceptions:
sulfatase deficiency, 16-hydroxylase deficiency,
adrenal hypoplasia, anencephaly). Intrauterine
death may, however, also occur at higher
values.
6. There seems no value in devising a point
System ascribing different weight factors to
individual estrogen values. Only normal or
abnormal states can be determined, with the
. whole curve being considered.
b) Fall in estrogen, time factor, diabetes
If we define a fall in estrogen äs a sudden pre-
cipitous decrease from one day to the next
without return to normal values, then this was
never observed in living fetuses. If it does
occur the fetus is most probably dead or dying.
It follows that the often discussed time factor in
the delay with which laboratory results are
obtained is unimportant in terms of hours or
even days. From that point of view plasma
against 24-hour urine analyses are equally valu-
able. It is much more important to have precise
data determined repeatedly so- that the time
course of excretion can be assessed. The only
exception in our opinion are diabetic mothers in
the last weeks of pregnancy where daily estrogen
determinations and less so pregnandiol determin-
ations, are of certain value.
3 Discussion
The most important result of this work is the
frequently observed temporal shift between
decreased estrogen excretion and pregnandiol
excretion in chronic impairment of the
nutritive function of the placenta. This can
only be understood if we assume that estrogen
excretion is limited not by the placental but
by the fetal compartment and that the fetus is
capable of synthetizing normal amounts of
estrogen precursors from C2 groups even in
chronic placental insufficiency. A number of
partly new results [5, 7, 14, 15, 21, 22, 23] that
cannot be dealt with in detail here support this
conclusion. It- may be assumed, at least äs a
working hypothesis, that decreased estrogen
excretion during pregnancy is probably due to
a disturbance in the fetal adrenal or liver and is
thus secondary to primary placental insufficiency.
Placental sulfatase lack, fetal adrenal hypoplasia
arid anencephalus are exceptions, äs mentioned
previously.
In a similar fashion pregnandiol reflects pla-
cental function [l, 2, 8, 9, 10,13]. Not only the
fetus but also the placenta is capable of
compensating some defects [21] äs witnessed
by capillary hyperplasia in hypofunction. This
compensation may lead to improved hormone
excretion during the further course of pregnancy
after a period of low hormone excretion. Such
cases are usually called "erroneously pathological"
in retrospective.
Our model with 4 factors (estrogen = fetus,
placenta = pregnandiol, fetal and placental
compensation) explains the results of this work.
Particularly it seems proven that pregnandiol
reflects the nutritive function of the placenta
and not some other function that may be un-
important for fetal well being. This Stresses the
finding of NAEYE [14] showing that the fetal
adrenal cortex and other organs are retarded in
weight to a greater extent in intrauterine growth
retardation than the birth weights o£ such new-
borns. Less severe injury to fetal organs could
thus be possible without macroscopically visible
dystrophy of the fetus: This would explain why
in risk group IV only slightly more than half
the infants were SGA. This wöttld also lead to
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thc conclusion that cases in risk group II are to
be considered äs at risk and should be treated
prophylactically. If we consider it ouraim to
diagnose all cases with placental insuf ficiency,
if possible before injury to the fetus is severe,
then we must not only have hormonal conttol
but also hormonal preventive control.
We believe that the determination of both
estrogen and pregnandiol is a reliable System
for this purpose. In our perinatal practice this
Interpretation o£ both endocrine parameters has
proved of value. A current study indicates that
three combined hormone determinations be-
tween weeks 20 and 26 are of great value for the
prognosis of risk of intrauterine growth re-
tardation. In contrast to many others, e. g.
KUSS [12], we believe that in the future placental
parameters such äs pregnandiol will be of
considerable significance for the early re-
cognition of chronic placental insufficiency.
Early diagnosis will be particularly decisive if
and when a reliable therapy is discovered and
thus fetal injury is, perhaps, avoided. This i s being
studied.
Summary
A reliable method for surveillance of chronic impairment
of nutritive placental function is dcscribcd. Thc techniqucs
are simple, tested for their reliability, without nced for
isotopes or special apparatus and hcnce inexpensive.
Using 222 pregnancies at risk it is shown that thc simul-
taneous determination of a fetal (estrogen) and a placental
(pregnandiol) parameter makes the early diagnosis of in-
trauterine growth retardation possible. Estrogen diagno-
sis alone has a reliability of 90.1% with 1.8% falsely
pathological and 8.1% falsely normal findings (Tab. I).
Simultaneous pregnandiol determinations increase
the number of falsely pathological Undings to 8.1%
but reduce that of falsely normal ones to 2.7%. No
small for date (SGA) infants are found here. It consists of
5 cases of imminent (3 times actual) premature delivery
and one postmature one. Hence our technique indicates
the risk of intrauterine growth retardation in all cases but
not the risk of premature or postmature delivery.
Early diagnosis (from week 20) indicates that impairment
of placental function äs indicated by decreased preg-
nandiol excretion, occurs weeks or months earlier than
decreased estrogen excretion (Fig. 1). This can be
explained only by assuming that the rate of estrogen excre-
tion is usually not dependent on the placenta but on the
capacity of the fetal adrenals and liver. Thus our results
indirectly confirm those of others who claim that the fetus
can synthetize estrogen precursors without the need
for placental pregnenolon by using acetate. Thus it
appears that the synthetic pathway that is independent of
the placenta at the beginning plays a quantitative role also.
Since the placenta can form aromatic compounds even
when its nutritive function is severely impaired, our fin-
ding is further proof that estrogen excretion reflects
fetal and not fetoplacental well-being. It follows that
pathological estrogen excretion indicates, fetal injury
that has already occurred. The requirement that a sensi-
tive parameter of placental function be hence determined
in time is met by pregnandiol assays. Low pregnandiol
excretion often precedes low estrogen excretion which
leads to a SGAinfant, indicating that pregnandiol excretion
i s closely correlated to placental nutritive function.
Synthetic reactions in thc fetus require cnergy and hence
dcpend on thc placenta. Normal estrogen excretion
frequently observed in the presence of prolonged
decreased pregnandiol excretion must hence indicate
that the fetus can compensate for placental insuffi-
ciency. In the placenta this can be demonstrated by hyper-
plasia of thc capillaries. This is reflccted in the undu-
lating excretion of pregnandiol (Fig, 1), where compcn-
sation (new vcssel formation) and depression (lesion of
vessels) make these contradictory placental processes
"visible". The functional unity of the fetus and the pla-
centa i s finally also demonstrated by thc fact thateach
prolonged compcnsatory phase of thc placenta is responded
to by the fetus with a clearly compensatory excretion of
estrogen (Fig. 1). Decreasing pregnandiol excretion, on
the other band, is accompanied by Stagnation in estrogen
excretion, indicating delayed fetal growth. This paper is
the first to demonstrate a relationship between placental
morphology and fetoplacental endocrinology. Four
risk groups are proposed (Tab. II). The model is based
on 4 assumptions:
1. Estrogen excretion is a fetal and not a fetoplacental
parameter;
2. Pregnandiol excretion is a parameter of placental
nutritive function;
3. Fetal compensatory capacity;
4. Placental compensatory capacity.
The model permits us to Interpret our data. The frequency
of SGA infants increases from risk group I (normal ex-
cretion of both hormones, no SGA infants), through risk
group II (only pregnandiol excretion pathological, 11.5%
SGA newborns) and risk group III (only estrogen excre-
tion pathological, 26% SGA infants) to risk group IV
(both hormone excretions pathological, 55.4% SGA infants).
Thedegree of risk can be estimatcd with our model. Risk
group II indicates slight, beginning EPH gcstosis. Treat-
ment in time maintains normal estrogen excretion with fre-
quently low pregnandiol valucs. If control and treatment
are neglected the picture frequently changes to group IV
and danger to the fetus is considcrably increascd (Fig. 2).
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It is slowly being realized in perinatal medicine that the
therapy of chronic placental insufficiency must be pro-
longed in Order to be successful. Early diagnosis is a prime
requirement. Our data show that this is possible in the
case of placental insufficiency before fetal damage occurs.
This makes early treatment possible. The large number of
SGA newborns in clinically apparently normal pregnan-
cies (30.1% of all intrauterine growth retardations) suggests
that all pregnancies should be controlled endocrino-
logically. This can only be realized by cooperation between
clinicians and practitioners.
Keywords: Endocrine model, intrauterine growth retardation; nutritive placental function, pregnandiol, total estrogen.
Zusammenfassung
Ein endokrinologisches Modell zur Diagnose der
intrauterinen Wachstumsverzögerung, demonstriert
durch Bestimmung der Gesamtöstrogen- und Pregnan-
diolausScheidung bei 222 Risikoschwangerschaften.
Es wird über ein praktikables, treffsicheres endokrino-
logisches System zur Überwachung der Schwangerschaft
bei chronischer Störung der nutritiven Plazentafunktion
berichtet. Die zur Hormonanalyse verwendeten Methoden
sind einfach, hinsichtlich ihrer Zuverlässigkeit geprüft,
ohne Verwendung radioaktiver Isotope oder spezieller
Meßgeräte durchführbar und somit jedem Laboratorium
ohne großen Kostenaufwand zugänglich.
An Hand einer Statistik von 222 Risikoschwangerschaften
wird nachgewiesen, daß bei gleichzeitiger Bestimmung
eines fetalen (Östrogene) und plazentaren (Pregnandiol)
Parameters das Risiko der intrauterinen Wachstums-
störung mit großer Sicherheit frühzeitig diagnostiziert
werden kann. Die alleinige Östrogenanalyse ergibt
eine Treffsicherheit von 90,1% bei 1,8% falsch patho-
logischen und 8,1% falsch normalen Befunden (Tab.
I). Durch die zusätzliche Pregnandiolanalyse erhöht
sich bei gemeinsamer Beurteilung zwar die Zahl der
falsch pathologischen Hormonbefunde auf 8,1%, j edoch
wird gleichzeitig die wichtigere Zahl der falsch nor-
malen Befunde auf 2,7% reduziert. Dieses Restkollek-
tiv enthält keine dystrophen Neugeborenen. Es setzt
sich zusammen aus 5 Fällen mit drohender (davon drei-
mal erfolger) Frühgeburt und einer echten Übertragung.
Somit wird in unserer Statistik durch die kombinierte
Hormonbestimmung das Risiko der intrauterinen Wachs-
tumsverzögerung in allen Fällen angezeigt, nicht jedoch das
Risiko der drohenden Frühgeburt und der Übertragung.
Bei frühzeitigem Beginn der endokrinologischen Diagno-
stik (ab 20. Woche) stellt sich heraus, daß eine Störung
der Plazentafunktion durch niedrige Pregnandiolaus-
scheidung Wochen bis Monate früher als durch niedrige
Östrogenausscheidung signalisiert wird (Abb. 1).
Dieses Ergebnis ist nur dann zu erklären, wenn man an-
nimmt, daß die Höhe der Östrogenausscheidung in der
Regel nicht von der Plazenta limitiert wird sondern von der
Funktionsfähigkeit der fetalen Leber und Nebennieren-
rinde. Somit bestätigen unsere Befunde indirekt die Mit-
teilungen anderer Autoren, wonach der Fet bei der Syn-
these von Östrogenvorstufen nicht auf das plazentare
Pregnenolon angewiesen ist sondern das Steroid-
gerüst de novo aus Acetat selbst zu bilden vermag.
Der in den Anfangsstufen plazentaunabhängige Synthese-
weg scheint daher nach unseren Beobachtungen auch
quantitativ eine Rolle zu spielen. Unter Einbeziehung der
experimentell bewiesenen Tatsache, daß die Aromatisie-
rungskapazität der Plazenta selbst bei schwer gestörter
nutritiver Funktion anscheinend nicht beeinträchtigt wird,
kann unsere Studie als ein weiterer Beweis dafür gelten,
daß die Östrogenausscheidung "weniger einen feto-
plazentaren sondern vielmehr einen fetalen Parameter
repräsentiert.
Die wichtige klinische Konsequenz hieraus ist, daß bei
pathologischer Östriolausscheidung eine bereits ein-
getretene Schädigung des Feten angenommen werden
muß. Die weitere Konsequenz ist die Forderung nach
einem plazentaren Parameter, der vor allen Dingen emp-
findlich, d.h. frühzeitig auf Plazentafunktionsstörungen
reagieren muß. Die vorliegende Arbeit beweist, daß die
Pregnandiolaüsscheidung nach unserer Methodik, im
Gegensatz zu anderen Ergebnissen, einen solchen
empfindlichen plazentaren Indikator darstellt. Da
niedriger Pregnandiolaüsscheidung häufig niedrige Östro-
genausscheidung mit einem dystrophen Kind folgen, ist
gleichzeitig der Beweis erbracht, daß die Pregnandiolaüs-
scheidung auch mit der nutritiven Partialfunktion der
Plazenta eng korreliert ist.
Energieverbrauchende Synthesereaktionen können im
Feten naturgemäß nicht völlig plazentaunabhängig statt-
finden. Zur Erklärung der von uns häufig beobachteten
normalen Östrogenausscheidung selbst bei langfristig
pathologischer Pregnandiolaüsscheidung muß daher
zusätzlich eine gewisse Kompensationsfähigkeit des Feten
im endokrinologischen Sinne angenommen werden, wie
sie vom respiratorischen Bereich her bekannt ist. Eine
solche Kompensationsfähigkeit läßt sich für die Plazenta
morphologisch in Form von Kapillarhyperplasie nach-
weisen. Sie findet ihren endokrinologischen Niederschlag
in wellenförmigen Pregnandiolausscheidungskurven (Abb.
1), bei denen Phasen der Kompensation (Gefäßneubil-
dung) und Depression (Gefäßschädigung usw.) die beiden
konkurrierenden Vorgänge in der Plazenta „sichtbar"
machen. Die fetoplazentare Funktionseinheit wird schließ-
lich endokrinologisch dadurch demonstriert, daß eine
jeweils längere plazentare Kompensationsphase vom Feten
durch einen deutlichen kompensatorischen Östrogen-
anstieg beantwortet wird (Abb. 1), während abfallende
Pregnandiolaüsscheidung vorwiegend von Stagnations-
phasen in der Östriolausscheidung, gleichbedeutend mit
verzögertem fetalen Wachstum, begleitet ist. Mit der vor-
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liegenden Arbeit wird somit erstmals der Zusammen-
hang zwischen Plazentamorphologie und fetoplazen-
tarer Endokrinologie dargelegt.
Unter Zusammenfassung der soeben diskutierten Faktoren
wird, ausgehend von den vier möglichen Kombinationen
der östrogen- und Pregnandiolausscheidung, ein System
von vier Risikogruppen vorgeschlagen (Tab. II). Das
Modell stützt sich auf vier Thesen:
1. Östrogenausscheidung = fetaler (nicht fetoplazen-
tarer) Parameter.
2. Pregnandiolausscheidung = Parameter der nutri-
tiven Plazentafunktion.
3. Endokrinologische Kompensationsfähigkeit des
Feten.
4. Endokrinologische Kompensationsfähigkeit der
Plazenta.
Das Modell gestattet eine zwanglose Erklärung der Ergeb-
nisse unserer Statistik. Die Häufigkeit dystropher Neu-
geborener nimmt zu von Risikogruppe I (östrogen- und
Pregnandiolausscheidung normal, keine dystrophen Kin-
der) über Risikogruppe II (nur Pregnandiolausscheidung
pathologisch, 11,5% dystrophe Kinder) und Risikogruppe
III (nur Östrogenausscheidung pathologisch, 26% dystro-
phe Kinder) zu Risikogruppe IV (beide Hormonparameter
pathologisch, 55,4% dystrophe Kinder). Durch unser
Modell wird es daher möglich, die Höhe des Risikos
der intrauterinen Wachstumsretardierung abzuschät-
zen. So ist eine Hormonausscheidung der Risikogruppe
II typisch für die leichte bzw. beginnende EPH-Gestose.
Bei rechtzeitiger, guter Behandlung bleibt es bei normalem
östrogenanstieg mit oft weiterhin niedrigen Pregnandiol-
werten. Wird jedoch eine Überwachung und Therapie
unterlassen, dann mündet die Hormonausscheidung der
Gruppe II häufig in das Bild der Risikogruppe IV und
die Gefährdung für den Feten wächst erheblich (Fig. 2).
Es setzt sich in der Perinatalmedizin langsam die Erkennt-
nis durch, daß eine Therapie der chronisch gestörten
nutritiven Plazentafunktion nur durch langfristige An-
wendung Erfolg verspricht. Die Frühdiagnose ist Bedin-
gung für ein solches Vorgehen. Unsere Untersuchungen
zeigen, daß mit der kombinierten östrogen- und Pregnan-
diolbestimmung die verminderte nutritive Plazentafunk-
tion schon vor Eintritt einer Schädigung des Feten er-
kannt werden kann. Dadurch sind langfristige vorbeu-
gende therapeutische Maßnahmen möglich, die nach
unserer Erfahrung eine schwere intrauterine Mangel-
entwicklung vermeiden. Die hohe Zahl dystropher Neu-
geborener bei klinisch unauffälliger Schwangerschaft
(30,1% aller Fälle von intrauteriner Wachstumsstörung)
führt ferner zu der Forderung einer allgemeinen endo-
krinologischen Vorsorgeüberwachung aller Schwange-
ren. Dies kann nur durch intensive Zusammenarbeit
zwischen Praxis und Klinik realisiert werden.
Schlüsselwörter: Endokrinologisches Modell, Gesamtöstrogene, intrauterine Wachstumsverzögerung, nutritive Plazenta-
funktion, Pregnandiol.
Resume
Un modele d'endocrinologie pour le diagnostic du
trouble de croissance intra-uterine, demontre par P6va-
luation de l'estriolurie totale et de la pr£gnandiolurie
dans 222 grossesses avec risque.
L'article present traite d'un Systeme endocrinologique
praticable et sur pour le controle de la grossesse en cas de
trouble chronique de la fonction placentaire nutritive. Les
methodes d'analyse hormonale employees ici sont simples
et sures, et ne necessitent ni isotope radioactif ni appareils
de mesure speciaux; elles peuvent donc etre effectuees par
n'importe quel laboratoire sans frais excessifs.
S'appuyant sur une statistique de 222 grossesses avec
risque, on a reussi a prouver qu'en etablissant simultane-
ment un parametre foetal (oestrogene) et un parametre
placentaire (pregnandiol), on peut diagnostiquer ä temps
et sans une grande marge d'erreur le risque du trouble de
croissance intra-utorine. La seule analyse d'oestrogenes
atteint un quotient d'exactitude de 90,1% pour 1,8%
de resultats pathologiques faux et 8,1% ,de resultats
normaux faux (Tab. I). En comparant, en outre, Panalyse
du prognandiol avec la prec6dente, on obtinet certes
une augmentation des resultats hormonaux patho-
logiques faux jusqu'ä 8,1%, mais, par contre, une
reduction a 2,7% du nombre plus important des r6sul-
tats normaux faux. Ce groupe subsiduel ne comporte
aucune nouveau-ne dystrophique, mais 5 cas d'avortements
spontanes menagants (dont 3 complets) et un cas de trans-
mission authentique. On voit donc que notre statistique,
etablie par la definition hormonale combinee, revele le
risque du trouble de croissance intra-uterine dans tous les
cas, mais non celui d'un avortement spontane ou d'une
transmission.
En cherchant a etablir tot (ä partir de la 20eme scmaine) le
diagnostic endocrinologique, on s'est apergu que la pre-
gnandiolurie faible, preuve d'un trouble de la fonction
placentaire, se manifestait-des-semaines-ou des moi&
avant une estriolurie peu elevee (Fig. 1). Ce resultat ne
peut s'expliquer que par le fait que le degre d'estriolurie
est, d'une fagon gonerale, limite par le fonctionnement du
foie et de Tecorce surrenale du foetus et non pas par le
placenta. Cest ainsi que nos resultats confirment indirecte-
ment les etudes d'autres auteurs selon lesquelles, dans la
Synthese des oestro-£l«£ments, le foetus ne depend pas
du progn£nolon placentaire, mais peut constituer lui-
meme la formule de base de novo a partir de l'ac£-
tate. Cette voie de Synthese, independante du placenta,
nous semble donc devoir jouer aussi un role quantitatif.
Compte tenu du fait exporimental d£montre que la capa-
cito d'aromatisation du placenta ne semble pas £tre roduite
meme en cas de trouble grave de la fonction nutritive,
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notre etude prouve a son tour que Pestriolurie repro-
sente beaucoup plus un parametre foetal que foeto-
placentaite.
Sur le plan clinique, on peut en deduire surtout qu'en cas
d'estriolurie pathologique, on se trouve dejä probable-
ment en presence d'une lesion du foetus. De plus, on
doit aussi etablir un parametre placentaire qui soit surtout
sensible, c. a. d. de reaction rapide et precoce aux troubles
du fonctionnement placentaire. Dans le travail present,
avec nos methodes et au contraire d'autres resultats, la
pregnandiolurie apparait bien comme tenant ce role
d'indicateur placentaire «sensible». La pregnandiolurie
peu elevee etant suivie bien souvent d'une faible estriol-
urie avec enfant dystrophique, il semble prouve egäle-
ment qu'elle est etroitement liee aussi a la f onction partielle
nutritive du placenta.
Les reactions de Synthese consommatrices d'energie dans
le foetus ne peuvent pas naturellement avoir tout^a-fait
Heu independamment du placenta. Si nous voulons donc
expliquer nos observations frequentes d'estriolurie nor-
male meme en cas de pregnandiolurie pathologique
Na long terme, nous devons admettre que le foetus opere
une certaine compensation endocrinologique comme il en
existe une, on le sait, dans le domaine respiratoire. On
peut observer cette compensation placentaire sous la
forme morphologique d'hyperplasie capillaire. Sa repro-
duction endocrinologique a Heu sous forme de courbes
ondulatoires de pregnandiolurie (Fig. 1) oü les phases de
compensation (angiopoi'ese) et de depression (angiolyse
etc.) rendent «visibles» les deux processus concurrents
dans le placenta. L'unite de fonction foeto-placentaire se
manifeste enfin sur le plan endocrinologique en ceci qu'a
une phase de compensation placentaire respectivement
plus longue chez le foetus repond une Hausse compen-
satoire d'oestrogenes tres nette (Fig. 1), tandis que la pre-
gnandiolurie decroissante s'accompagne surtout de phases
de Stagnation dans l'estriolurie, signe d'une croissance
foetale retardee. C'est ainsi que Petude presente expose
pour la premiere fois les rapports qui existent entre la
morphologie placentaire et l'endocrinologie foeto-
placentaire.
En resume des facteurs ci-dessus mentionnes et ä partir
des quatre combinaisons possibles d'estriolurie et de pre-
gnandiolutie, on peut elaborer un Systeme de quatre
groupes de risque (Tab. II) reposant sur les quatre theses
suivantes:
1. Estriolurie = parametre foetal (non foeto-placen-
taire);
2. pr£gnandiolurie = pararhetre de la fonction placen-
taire nutritive;
3. capacito de compensation endocrinologique du
foetus;
4. capacite de compensation endocrinologique du
placenta.
Ce modele nous permet d'interpreter les resultats de notre
statistique comme suit: La frequence des nouveaux-nes
dystrophiques augmente du groupe de risque I (estriol-
urie et pregnandiolurie normales, pas d'enfants dystro-
phiques) au groupe de risque II (seule prdgnandiolurie
pathologique, 11,5% d'enfants dystrophiques), puis au
groupe de risque III (seule estriolurie pathologique, 26%
d'enfants dystrophiques) jusqu'äu groupe de risque IV
(les deux parametres hormonaux pathologiques, 55,4%
d'enfants dystrophiques). Gräce a ce modele, il nous est
donc possible ä'evaluer le degro de risque du retarde-
ment de la croissance intra-uterine. C'est ainsi qu'un
hormonurie du groupe de risque II est typique pour la
gestose EPH legere ou commen^ante. Un bon traitement
applique a temps maintient une hausse normale d'oestro-
genes avec, souvent, des valeurs de pregnandiol encore
basses. Si, toutefois, la patiente reste sans contröle ni the-
rapie, l'hormonurie du groupe II rejoint souvent la courbe
du groupe IV, avec accroissement considerable du danger
pour le foetus (Fig. 2).
On reconnait enfin de plus en plus en medecine perinatale
qu'une therapie de la fonction placentaire nutritive soumise
ä un trouble chronique ne peut avoir des chances de succes
qu'a condition d'etre appliquee a long terme, ce qui pre-
suppose un diagnostic precoce. Nos propres recherches
prouvent qu'on peut deceler par Tevaluation combinee
des oestrogenes et du pregnandiol une reduction de la
fonction placentaire nutritive avant meme que n'apparaisse
une lesion du foetus, ce qui permet de prendre des mesures
therapeutiques preventives ä long terme qui, selon notre
experience, empechent une malnutrition intra-uterine
grave. Le nombre eleve des nouveaux-nes dystrophiques
consecutifs ä des grossesses cliniquement normales (30,1%
de tous les cas de trouble de croissance intra-uterine) nous
amene egalement ä recommander un contröle endocrino-
logique preventif goneral de toutes les femmes ^ence-
intes, ce qui n'est possible qu'a condition de collaboration
6troite entre les cabinets de consultation et l'hopital.
Mots-cles: Fonction placentaire nutritive, modele endocrinologique, oestrogenes totaux, pregnandiol, retardement de la
croissance intra-uterine.
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